Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

University of California San Diego researchers have identified a U-shaped association between high-density lipoprotein (HDL) ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Pharmaceuticals announced that the Therapeutic Goods Administration, TGA, has approved SYFOVRE or pegcetacoplan, for the ...

The following is a summary of “Neuroretinal and RPE changes and susceptibility to Age-Related Macular Degeneration: insights ...

About SYFOVRE® (pegcetacoplan injection) SYFOVRE ® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide ...